gish cv july 23 2014

5/21/2018 Gish CV July 23 2014

1/225

Table of Contents

PagePROFESSIONAL INFORMATION

A. LICENSURE & CERTIFICATIONS ............................................................................ 1B EDUCATION ............................................................................................................. 2C. POST GRADUATE EDUCATION .............................................................................. 2D. HONORS ................................................................................................................... 2E. NATIONAL FOUNDATION HONORS ........................................................................ 2F. SOCIETY MEMBERSHIPS ........................................................................................ 2G. LANGUAGES ............................................................................................................ 2

BIOGRAPHY...........................................................................................................................3-6

A. PERSONAL STATEMENT ......................................................................................... 5B. EXPANDED RESEARCH .......................................................................................... 5C. PRESS RELEASE - HEPATITIS B FOUNDATION .................................................... 6D. FACULTY APPOINTMENTS ..................................................................................7-8E. EMPLOYMENT AND STAFF POSITIONS ............................................................ 8-10F. STATE OF CALIFORNIA CONSULTANT POSITIONS ............................................ 10G. CONSULTANT POSITIONS .................................................................................... 11H. BUSINESS POSITIONS .......................................................................................... 11I. RESEARCH SUPPORT...................................................................................... 12-30J. UCSD RESEARCH / ADVISORY ....................................................................... 31-32K. COINVESTIGATOR: GASTROINTESTINAL TRIALS ......................................... 32-33

TEACHING ACTIVITIES...................................................................................................... 34-35

A. COMMITTEES .................................................................................................... 35-41B. BOARD ACTIVITIES ........................................................................................... 42-44C. EDITORIAL ACTIVITIES .......................................................................................... 45D. MENTEE LIST .................................................................................................... 46-48E. CLINICAL EXAM SESSIONS ................................................................................... 48

PUBLICATIONS

A. PEER REVIEW ORIGINAL PUBLICATIONS ...................................................... 49-64B. SUBMITTED FOR PUBLICATION ...................................................................... 65-66C. REVIEW ARTICLES ........................................................................................... 67-70D. PUBLIC POLICY ORIGINAL MANUSCRIPT ............................................................ 70E. NEWLETTERS......................................................................................................... 71F. BOOK CHAPTER & EDITORIALS....................................................................... 72-75G. CASE REPORTS & LETTER TO THE EDITORS .................................................... 75H. EDITOR / REVIEWER ........................................................................................ 76-79I. UCSD ...................................................................................................................... 80J. ABSTRACTS ..................................................................................................... 81-112

i

5/21/2018 Gish CV July 23 2014

2/225

............................................................................................................................................ Page

OTHER

CME PRESENTATIONS AND PUBLICATIONS ............................................................... 113-119FEDERAL AND STATE HEARINGS ....................................................................................... 120

EDUCATIONAL EVENTS ....................................................................................................... 120SPECIAL COURSES ATTENDED ................................................................................... 121-122COMMUNITY SERVICE and MEDIA APPEARANCES .................................................... 122-131INTERNATIONAL COMMUNITY PROGRAMS ....................................................................... 132INTERNET SITES AND PUBLICATIONS ............................................................................... 133INVITED LECTURES: NATIONAL AND INTERNATIONAL .............................................. 134-146INVITED LECTURES: REGIONAL ................................................................................... 147-195

AWARDS, CERTIFICATES, AND HONORS .................................................................... 196-197CONSULTANT: ACKNOWLEDGEMENT AS A CONTRIBUTOR / CME ACTIVITIES ...... 198-217HISTORICAL PRACTICE ADDRESSES AND OUTREACH SITES ................................. 218-219RESEARCH SUMMARY .................................................................................................. 220-221FORMER PRACTICE LEADERSHIP ...................................................................................... 222

DISCLOSURES...................................................................................................................... 223PHARMACEUTICAL COMPANY RELATIONSHIPS ............................................................... 223SPEAKERS BUREAU ............................................................................................................. 223

ii

5/21/2018 Gish CV July 23 2014

3/225

Curriculum Vitae

ROBERT G. GISH, M.D.

PROFESSIONAL INFORMATION

8/31/2013PresentRobert G. Gish MD, PrincipalRobert G. Gish, Consultants LLC6022 La Jolla Mesa DriveLa Jolla, California 92037Cell phone:1 858 229 9865Fax:1 858 886 7093Email:[email protected] address:robertgish.com

10/1/2013Present(Adjunct) Professor of Clinical Medicine

University of Nevada, Las Vegas10/1/2013PresentSenior Medical DirectorSt. Josephs Hospital and Medical CenterPhoenix, Arizona

1/31/2014PresentMedical DirectorHepatitis B Foundationhttp://hepb.org/index.html

5/1/2014PresentClincial Professor of Medicine (Consultant)

Stanford Hospital and Medical CenterStanford, California

PERSONAL INFORMATION

Date of Birth: September 18, 1955SSN: Available upon requestMarital Status: MarriedHome Address: San Diego, CaliforniaBirthplace: Chicago, IllinoisCitizenship: U.S.A.

LICENSURE

State of California, G-045632State of Nevada,

772112State of Arizona, 48551

BOARD CERTIFICATION

1984 Internal MedicineABIM 901811987 GastroenterologyABIM 90181 (MOC active)2007 CAQ Liver TransplantationABIM 90181
mailto:[email protected]:[email protected]:[email protected]://robertgish.com/http://robertgish.com/http://robertgish.com/http://robertgish.com/mailto:[email protected]

5/21/2018 Gish CV July 23 2014

4/225

Curriculum VitaeROBERT G. GISH, M.D. 2

EDUCATION

9/1/19736/15/1977 Pharmaceutical SciencesUniversity of Kansas

Lawrence, Kansas

9/1/19776/15/1980 Medical DoctorUniversity of Kansas School of MedicineKansas City, Kansas

POSTGRADUATE EDUCATION

6/1/19805/30/1981 Internship in Internal MedicineUniversity of California, San DiegoSan Diego, California

6/1/19816/30/1983 Residency in Internal Medicine

University of California, San DiegoSan Diego, California

7/1/19845/30/1988 Fellowship in Gastroenterology and HepatologyUniversity of California, Los AngelesLos Angeles, California

NATIONAL HONORS Alpha Omega Alpha

NATIONAL FOUNDATION HONORS

2002 Salute to Excellence: American Liver Foundation, 2/9/2002

SOCIETY MEMBERSHIPS

American Association for the Study of Liver DiseaseAmerican Gastroenterological AssociationAmerican Society of Transplant PhysiciansAmerican College of PhysiciansAsia Pacific Association for the Study of the LiverCalifornia Medical AssociationEuropean Association for the Study of the LiverInternational Liver Cancer Association

American Liver FoundationAmerican Transplant SocietyInternational Coalition of Hepatology Educators

LANGUAGES

EnglishSpanishVietnameseFrench

5/21/2018 Gish CV July 23 2014

5/225


BIOGRAPHY

Dr. Gish began his medical training in 1974 when he was enrolled into the Pharmacy School atthe University of Kansas. He transferred to the University of Kansas Medical School in 1977 andfinished his MD degree in 1980.

Dr. Gish went on to complete a 3 year Internal Medicine residency at the University of Califor-

nia, San Diego and a 4 year Gastroenterology and Hepatology fellowship at the University of

California Los Angeles during which time he was awarded the NIH Physician Scientist Award to

study calcium signaling in liver cells.

After completing his training, Dr. Gish moved to San Francisco and took a position at the

California Pacific Medical Center (formerly known as Pacific Presbyterian Hospital). He became

the Co- Medical Director of the Liver Transplant Program in 1988 and then the Medical Director

of the Liver Transplant Program in 1994. In that role he developed an outreach program that

eventually served over 35,000 patients in the Northern California and Nevada regions, and

made the CPMC a leading liver transplant center.

Dr. Gish has had and continues to have an active research program in viral hepatitis, liver

transplant, bio artificial liver, and public policy especially related to liver cancer, liver transplanta-

tion and viral hepatitis. Although his primary research focus is clinical research, he frequently

collaborates with basic scientists in his research activities. He has published more than 500

original articles, review articles, abstracts and book chapters.

Dr. Gish is also actively involved in numerous professional societies, and is a long-term member

of the American Association for the Study of Liver Disease, European Association for the Study

of Liver Disease, Asian Pacific Association for the Study of the Liver, and the American Society

of Transplant Physicians.

He is a fellow of both the American College of Physicians and a long-term member of the

American Association for the Study of Liver Disease. Dr. Gish has served on the editorial

boards of American Journal of Gastroenterology, Journal of Hepatology, Digestive Diseases

and Sciences, Gastroenterology, Hepatology, Liver Transplantation and Surgery, and Journal of

Viral Hepatitis. He has co-authored a public health policy for liver health in Vietnam and is also

assisting with the development of health care policies in Armenia and the Philippines.

In December 2010, Dr. Gish moved to San Diego to join the faculty of UCSD as a Clinical

Professor of Medicine, Section Chief of Hepatology, and Director of the Center of Excellence for

Hepatobiliary Disease and Abdominal Transplantation (C.H.A.T.).

In September of 2013, Dr. Gish left UCSD to form a consulting company, Robert G. GishConsultants LLC to provide consultative support to Hepatology Centers and Liver TransplantPrograms who wish to start or grow their programs through pathways of quality and optimalpatient care that is integrated with research and education. In September of 2013, Dr Gish

joined Dr Manch at St Josephs Hospital and Medical Center to start a liver and liver transplantcenter which continues to be an ogoing venture. On April 1, 2014, Dr Gish joined the Stanford

5/21/2018 Gish CV July 23 2014

6/225


BIOGRAPHY: Continued

Department of Medicine, Division of Gastroenterology and Hepatology and Liver TransplantService Line as a Staff Physician with major roles in inreach and outreach as well as programdevelopment. Over the years of 2012 to 2014, Dr Gish has been and continues to be very active

with the National Viral Hepatitis Round Table (NVHR) a patient and community advocacy non-profit organization. In February of 2014, Dr Gish joined the Hepatitis B Foundation, (HBF) as theirmedical director to lend his policy, advocacy and clinical science skills to their amametaium.

Today, Dr. Gish is a Clinical Professor of Medicine (Adjunct) at the University of Nevada in Las

Vegas where he continues to teach and is a senior consultant at St Josephs Medical Center in

Phoenix. And Clinical Professor of Medicine at Stanford University (Consultant).

LIVER CENTERS AND LIVER TRANSPLANT PROGRAMS

Dr. Gish became the Co-Medical Director of the Liver Transplant Program at the California

Pacific Medical Center in 1988. He developed an outreach program that now serves over

35,000 patients in Northern California and Nevada, making CPMC a leading liver transplantcenter. Dr. Gish joined the faculty of University of California San Diego in several capacities,

including Director of the Center for Hepatobiliary Disease and Abdominal Transplantation. He

also became Director of Clinical Hepatology at UCSD in 2010. His research on Regional Review

Boards may also change public policies on liver transplants in the United States. This research

supports the replacement of the current RRB system with a national review board that uses

clinical expertise to assign priorities. The goal of this system is to allocate organs equitably while

improving compliance with the HHS Final Rule. His appointment with the Liver Transplant

Program and Department of Medicine at Stanford University began on April 30, 2014.

RESEARCH

Dr. Gishs pharmaceutical research includes a 2011 Phase III study on the effects of BI

201335, pegylated interferon-a and ribavirin on patients infected with genotype 1 chronic

hepatitis C. He is also the principle investigator in an ongoing study on screening for viral

hepatitis and its economic effects on healthcare. Another study currently being conducted by Dr.

Gish involves the analysis of liver patients at UCSD.

Dr. Gish was the principle investigator in a study that was started in 2012 to investigate the

effects of PSI-352938, PSE-7977 and Ribavirin in patients with Chronic HCV. He is also

currently investigating the challenges of educating Asians in San Diego County on Hepatitis B ina study that began in 2012.

Dr. Gish was an investigator in studies that led to the development of tests for HBV and HCV

and most recently a 2005 study on DNA HBV genotyping and molecular profiling in newly

recruited, HBV and HCV patients. He was also an investigator in a 2006 study that used

molecular signatures to predict interferon response in patients infected with Hepatitis C.

Dr Gishs research now includes co-leading a research program with Arrowhead Pharmaceuti-

cals on iRNA treatment of HBV infection.

5/21/2018 Gish CV July 23 2014

7/225



HEALTH POLICY AND PATIENT ADVOCACY

Dr. Gish has been involved with patient care and patient advocacy groups dating back to 1988

when he became involved with the American Liver Foundation. Since that time, he has beenactive with a number of organizations including the National Viral Hepatitis Roundtable, Viral

Hepatitis Action Coalition, the Fair Foundation, Center for Eradication of Viral Hepatitis/Asia

Pacific Organization, HEP- DART, World Health Organization, Centers for Disease Control,

Hepatitis B Free (San Francisco and San Diego), Hepatitis B Foundation, Hepatitis C Caring

Ambassadors, Viral Hepatitis Foundation, and Hepatitis Foundation for Vietnam.

Dr. Gishs international advocacy career focuses onpublic policy in Vietnam, Philippines, and

Armenia. His team wrote a white paper on Health Care and Liver Health in Vietnam that was

published in a peer-reviewed publication. Additional projects in Vietnam and the Philippines

include protocols that advance screening for viral hepatitis and linkage to care, as well as

global liver health issues including obesity, fatty liver, and alcohol induced liver disease. Thenewest addition to Dr. Gishs global health policy work is in Armenia, where he is develop ing a

white paper for that countrys 5-year Liver Health Policy.

PERSONAL STATEMENT

My clinical research and studies focus on viral hepatitis, liver transplant, bioartificial liver, public

policy especially related to liver transplantation and viral hepatitis. Clinical trials for a variety of

antiviral therapies and new bioartificial livers systems will continue to be a major focus of my

practice. We will use databases to help uncover associations between liver cancer and certain

cancer biomarkers. In addition we will be building a multidisciplinary liver cancer program and

will integrate models of HCC signaling into our program. My background includes training in viralhepatitis clinical trials and liver cancer trials. I plan to have a focus on biomarkers for liver

cancer to help guide treatment decisions and therapies. I have 25 years of experience as a

clinician and clinical investigator in the realm of liver disease, liver transplant and liver cancer. I

do a variety of educational programs for Pharma including promotional talks that are highly

regulated by the FDA and the Pharma Code: these funds are all recycled into research,

education, policy, philanthropy and supporting international health care.

EXPANDED RESEARCH

Dr. Gishs work focuses on the epidemiology of liver disease, biomarkers for liver disease and

multi-targeted therapies for liver cancer such as protein kinase inhibitors, fibroblast growthfactors and iRNA technologies to treat viral hepatitis. His research also includes the diagnosis

and treatment of liver failure, liver transplantation, and viral hepatitis, both B and C variants.

Recent clinical studies have focused on the Hepatitis B Virus within the Asian population at

large as well as exosomes, liver failure, bioartifical livers and international health policy.

5/21/2018 Gish CV July 23 2014

8/225



PRESS RELEASEFebruary 2014

Hepatitis B Foundation Welcomes Dr. Robert Gish as Medical Director

Renowned leader in the field of liver disease takes on new role leading advocacy and research

DOYLESTOWN, Pa. (February 2014) The Hepatitis B Foundation (www.hepb.org), the only

national nonprofit organization solely dedicated to finding a cure for hepatitis B, is pleased to

announce that Robert G. Gish, M.D., became the foundations medical director on Jan. 30,

2014. An internationally renowned medical researcher in the field of viral hepatitis, Dr. Gish has

made invaluable contributions to the understanding and treatment of hepatitis B, which is the

worlds leading cause of liver cancer. A longtime supporter of the foundations mission and a

member of the Scientific Advisory Board, Dr. Gishs new role will further strengthen its research

and advocacy efforts worldwide. We are delighted to welcome Dr. Gish to our board, said Dr.

W. Thomas London, senior member emeritus of Fox Chase Cancer Center and vice presidentof the board of directors of the Hepatitis B Foundation. He has long been a leader in the field

and has extensive experience in the conduct of clinical trials of new drugs to combat chronic

hepatitis B. His leadership as medical director will help us advance the treatment and prevent

the severe consequences of this potentially deadly disease. After receiving his medical degree

in 1980, Dr. Gish quickly developed a keen interest in liver health, focusing his research on

investigation of viral hepatitis B and C. He went on to become medical director of the liver

transplant program at California Pacific Medical Center in 1994, developing an outreach

program that eventually served more than 35,000 patients in northern California and Nevada

and made the medical center a leading liver transplant center. Over the course of his career, Dr.

Gish has published more than 600 original articles, abstracts and book chapters and more than

120 peer-reviewed publications. Today, he is a clinical professor of Medicine at the University ofNevada in Las Vegas, where he continues to teach, and is a senior consultant at St. Josephs

Medical Center in Phoenix. In 2013, he formed Robert G. Gish Consultants LLC to support liver

health and transplant programs with operations, outreach, compliance, financial planning and

program development in the U.S. and Asia. Dr. Gishs background is a perfect fit for the work

we do here at the Foundation and our Baruch S. B lumberg Institute, said Dr. Timothy Block,

president of the Hepatitis B Foundation and also a professor of Microbiology at Drexel Universi-

ty. We are honored that Dr. Gish has agreed to become our medical director and look forward

to many years of collaboration so we can finally put an end to this serious liver infection. To

learn more about Dr. Robert Gish, visit his website.

5/21/2018 Gish CV July 23 2014

9/225


FACULTY APPOINTMENTS

* Please note: The following dates are best estimates due to lack of evidenced documentation:

7/1/19836/30/1984 Emergency Room Associate

Claremont HospitalClaremont, California

6/1/19855/30/1988 Research AssociateDivision of GastroenterologyUniversity of California, Los AngelesLos Angeles, California

9/119886/1/1993 Research AssociateMedical Research InstituteCalifornia Pacific Medical CenterUniversity of the Pacific

San Francisco, California

9/1/19917/2/1996 Assistant Clinical Professor of MedicineUniversity of California, DavisSacramento, California

7/1/19916/30/1996 Valley Children's HospitalLiver Disease ProgramFresno, California

7/1/19936/30/1998 Merced Community HospitalFamily Medicine ProgramUniversity of California, DavisSacramento, California

7/1/19946/30/1998 Assistant Clinical Professor of MedicineUniversity of Nevada, RenoReno, Nevada

7/1/19986/30/2005 Associate Clinical Professor of MedicineUniversity of Nevada, RenoReno, Nevada

7/1/20056/30/2006 Clinical Professor of MedicineUniversity of Nevada, Las Vegas, Nevada

8/1/19951/1/2010 Medical Director of Liver Transplant ProgramCalifornia Pacific Medical CenterSan Francisco, California

9/1/19966/1/1999 Assistant Clinical Professor of MedicineUniversity of California, San FranciscoSan Francisco, California

5/21/2018 Gish CV July 23 2014

10/225


FACULTY APPOINTMENTS: Continued

7/30/19996/30/2009 Associate Clinical Professor of MedicineUniversity of California, San FranciscoSan Francisco, California

7/1/20098/30/2010 Clinical Professor of MedicineUniversity of California, San FranciscoSan Francisco, California

9/1/20108/30/2013 Clinical Professor of MedicineUniversity of California, School of MedicineSan Diego, California

1/1/2014Present Clinical Professor,Department of Internal Medicine, AdjucntUniversity of Nevada School of Medicine,

Las Vegas, Nevada

EMPLOYMENT AND STAFF POSITIONS

19751977 Research AssociateMcCollum LaboratoriesUniversity of KansasLawrence, Kansas

19821983 Per diem Physician

Medicus Medical GroupSan Diego, California

19821983 Per diem PhysicianKaiser PermanenteSan Diego, California

19821983 On call MD: Life Flight-Critical Air TransportSan Diego, California

19831984 Per diem PhysicianPioneer Memorial Hospital

Brawley, California

19831984 Emergency Clinic and Medical Doctor at Clarmmont HospitalIndustrial Medical CentersSan Diego, California

5/21/2018 Gish CV July 23 2014

11/225


EMPLOYMENT AND STAFF POSITIONS: Continued

19841986 Emergency Physician: Serra Memorial HospitalEmergency MedicineSun Valley, California

19861988 ConsultantSherman Oaks Community HospitalSherman Oaks, California

1987 ConsultantPhillip Edelman, M.D.Occupational MedicineOrange, California

1987 ConsultantWashington Medical Center

Culver City, California

19871988 ConsultantValley PresbyterianVan Nuys, California

1988 Staff PhysicianOliveview Medical CenterSylmar, California

1988 ConsultantWest Hills Medical CenterConoga Park, California

19881989 ConsultantMt. Zion Medical CenterSan Francisco, California

19901991 ConsultantSeton Medical CenterDaly City, California

19901995 ConsultantValley Children's HospitalFresno, California

19932006 ConsultantEnloe Hospital,Chico, California

20022009 ConsultantSunrise HospitalLas Vegas, NV

5/21/2018 Gish CV July 23 2014

12/225


EMPLOYMENT AND STAFF POSITIONS: Continued

19882010 Staff PhysicianCalifornia Pacific Medical CenterSan Francisco, California

20092010 PhysicianSt. Lukes HospitalSan Francisco, California

19912010 ConsultantHighland HospitalOakland, California

19962010 ConsultantMedical Staff, Department of MedicineJohn Muir Medical CenterWalnut Creek, California

19972006 ConsultantAlta Bates Medical CenterMedicine and Family PracticeBerkeley, California

20032010 PhysicianSaint Marys Medical CenterSan Francisco, California

20102013 Medical Director of Center for Hepatobiliary Disease and Abdominal

Transplantation (CHAT)Chief of HepatologyUniversity of California, San DiegoSan Diego, California

2014Present Medical Director, Staff PhysicianStanford Hospital and Medical CenterStanford, CA

STATE OF CALIFORNIA CONSULTANT POSITIONS

1996 State of CaliforniaDepartment of CorrectionsInfectious Disease Advisory Board

5/21/2018 Gish CV July 23 2014

13/225


CONSULTANT POSITIONS

2010Present Founding MemberCEVHAP (Coalition to Eradicate Viral Hepatitis in Asia Pacific).Singapore

20122014 Advisory Board/Steering Committee,National Viral Hepatitis Roundtable

20132014 Executive Committee Vice Chair, NVHR

BUSINESS POSITIONS

19992000 President and TreasurerPacific Hepatology and Gastroenterology Medical Group, P.C.San Francisco, California

19992001 President and CEOHepahope CorporationSan Francisco, California

20002005 PresidentPacific Hepatology and Gastroenterology Medical Group, P.C.San Francisco, California

2009Present President, Pacific Health Consortium LLC

19882010 Office address:California Pacific Medical Center2340 Clay StreetSan Francisco, California 94115

20102013 U.C. San DiegoMedical Director of Center for Hepatobiliary Disease and

Abdominal Transplantation (CHAT)Chief of HepatologyProfessor of Medicine350 Dickinson Street, Suite 342San Diego, California

8/31/2013 Robert G. Gish MDPresent Robert G. Gish Consultants, LLC

Business address:6022 La Jolla Mesa DriveSan Diego, CA 92037Cell phone: 1 858 229 9865Email:[email protected]: robertgish.com
mailto:[email protected]:[email protected]:[email protected]:[email protected]

5/21/2018 Gish CV July 23 2014

14/225


RESEARCH SUPPORT

19751977 Co-Investigator: NIH Grant #GM 22357. Ionization Kinetics ofCarbon Acids. University of Kansas. Grant award: $70,000.

19851988 Principle Investigator: National Institute of Environmental HealthSciences Physician Scientist Award. Grant award: $210,000.

19931995 Co-Investigator: Amgen grant. A Phase III, Randomized, Double-Blind Controlled Trial of Recombinant Methionyl InterferonConsensus (r-tetIFN-Con1) in Patients with Chronic Hepatitis CVirus (HCV) Infection. California Pacific Medical Center.Grant award: $187,604.

19931994 Co-Investigator: Loewy Fund grant. Development and Validationof a Standardized Interview for the Detection of Alcoholism inPatients Referred for Liver Transplantation. California Pacific

Medical Center. Grant award: $6,487.

19931998 Co-Investigator: NIH grant. Cytokines and Human AutoimmuneLiver Disease. Grant award: $579,800.

1994 Principle Investigator: Syntex grant. Ganciclovir for the Treatmentof Hepatitis B after Organ Transplantation. Grant award: $10,000.

1994 Principle Investigator: Schering Corporation grant. Interferon alfa-2b: Dose Escalation and Taper for the Treatment of Hepatitis C.Grant award: $15,000.

1995 Principle Investigator: PRI grant. Natural History of Hepatitis B.Grant award: $10,000.

1995 Co-Investigator: Chiron grant. Beta-Interferon for Retreatment ofHepatitis C. Grant award: $30,000.

19951997 Principle Investigator: Schering-Plough grant. Hepatitis CTreatment with Interferon with or without Phlebotomy.Grant award: $25,000.

19951997 Co-investigator: GlaxoWellcome grant. Study P110-008-Tucaresol Dose Escalation Drug Study for Hepatitis B.

Grant award: $35,000.

19961997 Co-Investigator: GlaxoWellcome grant. Study NUCA 3011- APlacebo-Controlled Study of Lamivudine and Intron-A in Patientswith Chronic Hepatitis B Infection who are Interferon Non-Responders. Grant award: $8,000.

5/21/2018 Gish CV July 23 2014

15/225


RESEARCH SUPPORT: Continued

19961997 Co-Investigator: GlaxoWellcome grant. Study NUCA3010- AStudy of Lamivudine or Placebo in Patients with Chronic HepatitisB Infection who are Treatment Naive. Grant award: $10,000.

19961997 Co-Investigator: GlaxoWellcome grant. Study NUCA3005-Lamivudine Open Label Program for Treatment of Patients withHepatitis B Viral Infection Post-Liver Transplantation.Grant award: $20,000.

19961997 Co-Investigator: GlaxoWellcome grant. Study NUCA2006- A PilotStudy to Assess the Safety and Efficacy of Lamivudine During theCourse of Liver Transplantation for Patients with Chronic HepatitisB Infection (nave study). Grant award: $35,000.

19962001 Principle Investigator: GlaxoWellcome grant. Study NUCA3017- AStudy of Extended LamivudineTtreatment for Hepatitis B PatientsPreviously Enrolled in Phase II or Phase III Lamivudine Trials.Grant award: $80,000.

19961997 Co-Investigator: Schering-Plough grant. Study C95-144- Interferonwith or without Ribavirin in Hepatitis C Patients with Relapse afterInterferon. Grant award: $158,000.

19961997 Co-Investigator: Schering-Plough grant. Study C95-132- IntronAMonotherapy vs. IntronA + Ribavirin for Treatment of ChronicHepatitis C in Interferon-naive Patients. Grant award: $178,000.

19961998 Principle Investigator: Schering-Plough grant. Interferon withRibavirin for Interferon Failure in Hepatitis C Patients.Grant award: $550,000.

19961997 Principle Investigator: Ciba Corning grant. Lab study of Mx proteinas a Marker for Injection Therapy. Grant award: $5,000.

19961999 Principle Investigator: GlaxoWellcome grant. Study NUCA3021-Lamivudine Compassionate Use Treatment Program for Subjectsof Three Life-Threatening Forms of Hepatitis B Infection.

19972000 Principle Investigator: Otsuka America Pharmaceutical Inc. Grant.Study 156-96-203; Multicenter, Randomized, Double-Blind,Placebo-Controlled, Dose-Ranging, Efficacy, Safety andPharmacokinetics Study of OPC 41061 in Hospitalized Patientswith Hyponatremia, Secondary to Liver Disease.Grant award: $150,000.

5/21/2018 Gish CV July 23 2014

16/225



19972002 Co-investigator: Roche BioScience grant. Study MYCO 2642- ARandomized, Double-Blind, Comparative Study of the Efficacyand Safety of Intravenous and Oral Mycophenolate Mofetil and

Azathioprine, Each in Combination with Cyclosporine (Neoral) andCorticosteroids in Liver Transplant Recipients.Grant award: $176,000.

19972002 Principle Investigator: GlaxoWellcome grant. Study NUCA 3016- ALong-term Epidemiologic Study of Patients who have Evidence ofPossible Durable Response to Lamivudine in Phase II or Phase IIITrials of Lamivudine. Grant award: $21,000.

19982000 Principle Investigator: Triangle Pharmaceuticals grant. Phase IClinical Trial of FTC for Patients who have Chronic HBV Infection.Grant award: $300,000.

19982001 Principle Investigator: Triangle Pharmaceuticals grant. Phase IIRollover Clinical Trial of FTC for Patients who have Chronic HBVInfection. Grant award: $200,000.

19981999 Principle Investigator: Bristol-Myers Squibb grant. Lobucavir vs.Interferon for patients who have not undergone previousTreatment with Interferon Therapy. Grant award: $75,000.

19992000 Principle Investigator: Bristol-Myers Squibb grant.200475 vs. Interferon for patients who have not undergoneprevious treatment with Interferon therapy. Grant award: $85,000.

19981999 Co-investigator: Bristol-Myers Squibb grant. Lobucavir for Patientswho have Failed Previous Treatment with Interferon Therapy.Grant award: $75,000.

19971998 Co-investigator: Matrix Pharmaceuticals grant. IntratumoralInjection of Cis-Platinum/Bovine Collagen for theTreatment ofHepatocellular Carcinoma and Metastatic Colon Cancer.Grant award: $30,000.

1998Present Principal Investigator: Schering-Plough grant. Interferon/RibavirinTreatment of Non-Responders and Relapsers. Grant award:

$750,000.

19982000 Principle Investigator: Schering-Plough grant. Study C98-169-Comparison of Intron AInduction Therapy + Rebetolvs. Intron

A+ Rebetolfor the Treatment of Adult Naive Subjects withChronic Hepatitis C Infected with HCV Genotypes 1, 2, 3, or 2/3.Grant award: $59,000.

5/21/2018 Gish CV July 23 2014

17/225



19982001 Principle Investigator: Hoffmann-LaRoche grant. StudyNV15496C- A Phase III Open-label, Randomized, Multicenter,Parallel Dose Efficacy and Safety Study Comparing Pegylated-Interferon -2a (RO 25-8310) to a Standard Regimen of Roferon

A in the Treatment of Patients with Chronic Hepatitis C. Grantaward: $148,000.

19972001 Principle Investigator: Schering-Plough grant. Study C96-318-Treatment of Relapse in Patients with Chronic Hepatitis CComparing Intron AMonotherapy vs. IntronA + Ribavirin.Grant award: $20,000.

19982001 Principle Investigator: An open-label, single arm Study to Evaluatethe Combination of Zenapax (daclizumab) and CellCept(mycophenolate mofetil) with Corticosteroids in the Prevention of

Acute Rejection in Primary Liver transplant Recipients. RochePharmaceuticals. Grant award: $17,500.

19971999 Principle Investigator: Schering-Plough grant. Study C97-010-Comparison of Peg-interferon vs. Intron Afor Treatment of AdultSubjects with Chronic Hepatitis C not Previously Treated withInterferon: Dose-finding study. Grant award: $105,000.

19992002 Principle Investigator: Hoffmann-LaRoche grant. Study #NV15801- A phase III,Rrandomized, Multicenter, Efficacy andSafety Study Comparing the Combination of Pegylated-interferon

-2a (Ro 25-8310) and Ribavirin with Rebetron A in theTreatment of Patients with Chronic Hepatitis C. Grant award:$68,000.

19992002 Principle Investigator: Hoffmann-LaRoche grant. Study NR15994-A randomized, open-label, multicenter, efficacy and safety Studyof Pegasys plus Ribavirin, Pegasysplus CellCept,Pegasys plus Amantadine, or Pegasys plus Amantadine plusRibavirin in Patients with Chronic HCV Infection who have notResponded to at least 12 Weeks of Treatment with Rebetron.Grant award: $75,000.

19992002 Principle Investigator: Gilead grant. Study GS98-437- A double-blind, randomized, placebo-controlled Study of Adefovir Dipivoxilfor the Treatment of Patients with HBeAg+ Chronic Hepatitis B Vi-rus Infection. Grant award: $106,000.

5/21/2018 Gish CV July 23 2014

18/225



19992006 Principle Investigator: Gilead Pharmaceuticals grant. Phase III &Rollover, Double-blind, randomized, placebo-controlled Study of

Adefovir Dipivoxil for Treatment of Patients with HBeAg+ ChronicHepatitis B Virus Infection with Open Label Long Term Follow Upof Safety, Efficacy, and Resistance of Adefovir.Grant award: $143,323.

20002001 Principle Investigator: Gilead grant. Study 472- Pharmacokineticsstudy (PK) of 48 weeks treatment with adefovir 10mg/day for HBVinfected, nucleoside treatment-nave patients with compensatedliver disease.

2000 Sub-Investigator: Bristol-Meyers Squibb grant. Long-Termrollover, assessment of safety and antiviral activity of open-labelentecavir plus lamivudine in chronic hepatitis B patients who haveviremia on monotherapy in other entecavir trials.Grant award: $32,571.

20002005 Sub-Investigator: Bristol-Meyers Squibb grant. A phase III study ofthe Safety and Antiviral Activity of Entecavir vs. Lamivudine in

Adults with Chronic Hepatitis B Infection who are Positive forHepatitis B E Antigen. Grant award: $75,867.

20002005 Sub-Investigator: Bristol-Meyers Squibb grant. A Phase III Studyof the Safety and Antiviral Activity of Entecavir vs. Lamivudine in

Adults with Chronic Hepatitis B Infection who are Negative forHepatitis B E-Antigen. Grant award: $29,911.

20002005 Sub-Investigator: Bristol-Meyers Squibb grant. A Phase III Studyof the Safety and Antiviral Activity of Entecavir vs. Lamivudine in

Adults with Chronic Hepatitis B Infection who are Negative forHepatitis B E-Antigen. Grant award: $40,048.

20002005 Sub-Investigator: Bristol-Meyers Squibb. Long-term Assessmentof Treatment Outcomes with Entecavir and Lamivudine forChronic Hepatitis B Infection in Patients who have Enrolled inPhase III Entecavir Trials. Grant award: $3,524.

20002005 Principle Investigator: Bristol-Meyers Squibb. Decompensated,

Comparison of the Efficacy and Safety of Entecavir vs. Adefovir inSubjects Chronically Infected with Hepatitis B virus with Evidenceof Lamivudine Resistance and Hepatic Decompensation.Grant award: $80,150.

2001 Principle Investigator: GlaxoSmithKline grant. Study Nuc2094 -Lamivudine and Adefovir Combination for the Treatment ofChronic HBV Infection.

5/21/2018 Gish CV July 23 2014

19/225



20012002 Principle Investigator: Scripps Consortium grant. Hepatitis CRegistry. Grant award: $5,000.

20012002 Principle Investigator: Bayer Pharmaceuticals grant. HCV 3.0assay development. Grant award: $6,000.

20012002 Co-Investigator: BioMeasure, Inc., grant. Lanreotide Study for theStudy of Acute GI Bleeding in Portal Hypertension.Grant award: $40,000.

20012002 Principle Investigator: Bristol-Meyers Squibb grant. Study 014-020- Entecavir vs. Lamivudine (52 weeks therapy) in AdultPatients with Chronic Hepatitis B who are Positive for Hepatitis Be-Antigen and Nave to Previous Therapy.

20012002 Principle Investigator: Roceh Pharmaceuticals: 8 weeks of Peg-Interferon +/- Ribavirin vs. Roferon 3 MU TIW + Ribavirin forPatients with Chronic Hepatitis C Co-infected with HIV, Nave toInterferon Therapy.

20012002 Sub-Investigator: Physician initiated study: Hepatitis ResourceNetwork. Peg-interferon -2b + Ribavirin for Treatment of ChronicHepatitis C Infection in HIV-infected Persons not PreviouslyTreated with Interferon.

20012002 Sub-Investigator: National Hemochromatosis Transplant Registrygrant. Prevalence of Hepatic Iron Overload and HFE Mutations

among Patients Undergoing Orthotopic Liver Transplantation(OLT): Interim Results from the National HemochromatosisTransplant Registry (NHTR) NIH.

20012006 Sub-Investigator: SciClone Pharmaceuticals grant. A multicenter,double-blinded study in patients with compensated non-cirrhosisdue to chronic hepatitis C who are non-responders to priorinterferon alfa + ribaviron therapy, comparing treatment withthymosin + peg-interferon with peg-interferon + placebo.Grant award: $289,756.

20012008 Sub-Investigator: SciClone Pharmaceuticals grant. A multicenter,

double-blinded study in patients with compensated cirrhosis dueto chronic hepatitis C who are non-responders to prior interferonalfa + ribaviron therapy, comparing treatment with thymosin + peg-interferon with peg-interferon + placebo. Grant award: $240,869.

5/21/2018 Gish CV July 23 2014

20/225



20012005 Sub-Investigator: Hoffman-LaRoche grant. A Phase III partiallydouble-blind study Evaluating the Efficacy and Safety of 40kDBranched Pegylated Interferon Combined withPlacebo or Lamivu-dine vs. Lamivudine in HBeAg- Positive Patients with ChronicHepatitis B. Grant award: $45,579.

20012006 Principle Investigator: Schering-Plough grant. Long term follow upProtocol to Assess Subjects after Completing 24 weeks ofSchering-Plough Research Institute (SPRI) Clinical Trial forChronic Hepatitis C. Grant award: $19,200.

20012005 Principle Investigator: Schering-Plough grant. Comparison of peg-interferon plus ribavirin given as a fixed dose or on a weightoptimized basis for treatment of chronic hepatitis C in previouslyuntreated adult subjects. Grant award: $41,950.

20022004 Principle Investigator: Roche Pharmaceuticals grant. A phase IIIpartially double-blinded Study Evaluating the Efficacy and Safetyof Pegasys with Placebo or Lamivudine Versus Lamivudine inHBeAg-PositivePpatients with Chronic Hepatitis B.

2002 Principle Investigator: Ortho-Biotech grant. Procrit vs. Placeboweekly to treat anemia for patients taking ribavirin + interferon orpeg-interferon.

2002 Principle Investigator: Akros Pharma grant. A randomized,double-blind placebo-controlled, ascending dose Study of the

Safety, Tolerability, Pharmacokinetics, andPpharmacodynamics ofJTK-003 inPpatients with Chronic Hepatitis C Infection for Non-responders to Previous Therapy.

20022003 Principle Investigator: ICN pharmaceuticals/Ribapharm grant. APhase I multiple-dose astudy to evaluate safety, tolerability, andpharmacokinetics of viramidine for patients with compensatedHCV.

2002 Principle Investigator: Chiron grant. Randomized, placebo-controlled study of the safety and efficacy of HBV/MF59 (vaccine)alone or in combination with lamivudine.

20022003 Principle Investigator: Bristol-Meyers Squibb grant. Entecavir vs.Lamivudine (52 weeks therapy) in Adult Patients with ChronicPepatitis B who have had an Incomplete Response to LamivudineTherapy.

5/21/2018 Gish CV July 23 2014

21/225



20022005 Principle Investigator: SciClone Pharmaceuticals grant. Thymosinfor HCV Non-responders Comparing Treatment with Thymosin

Alpha 1 + Peg-interferon Alpha-2a with Peg-interferon Alpha-2a +Placebo (Study 1: noncirrhotic; Study 2: cirrhotic).

20022005 Co-Investigator: NIH grant. Recurrent Hepatitis B after LiverTransplant. Grant award: $32,705.

20022005 Sub-Investigator: Roche Pharmaceuticals. A randomized, openlabel, multi-center, pilot study of Pegasys and Epivir-HBV as InitialTreatment of HBeAg- Negative Chronic Hepatitis B Infection.Grant award: $29,644.

20022003 Principle Investigator: Intermune grant. Double-blind, randomized,placebo-controlled Study of the Safety and Anti-fibrotic Efficacy ofGamma Interferon in Patients with Severe Liver Fibrosis orCirrhosis due to HCV.

20022003 Sub-investigator: Schering Corp. Comparison of Peg-interferonAlfa-2b plus Ribavirin Given as a Fixed Dose or on a WeightOptimized Basis for Treatment of Chronic Hepatitis in PreviouslyUntreated Adult Patients.

20022004 Principle Investigator: SciClone Pharmaceuticals grant. Trial ofzadaxin with transarterial chemoembolization in patients withunresectable hepatocellular chemoembolization with or withoutzadaxin therapy for 6 months. Award $240,000

20022003 Principle Investigator: ICN pharmaceuticals/Ribapharm grant. APhase II randomized Study to Evaluate the Efficacy of Viramidinefor Patients with Compensated HCV.

20022003 Principle Investigator: Eximias Pharmaceuticals. Thymataq vs.Doxorubicin for the Treatment of HCC. Grant award: $240,000

20022005 Principle Investigator: Valeant Pharmaceuticals grant. Phase IIdose-ranging Study of Viramidine in Combination with Pegasys inTreatment-nave Subjects with Chronic Hepatitis C Infection.Grant award: $292,559.

20022005 Sub-Investigator: Idenix Pharmaceuticals grant. A randomized,double-blind trial of Telbivudine vs.Llamivudine in Adults withCompensated Chronic Hepatitis B. Grant award: $106,427.

5/21/2018 Gish CV July 23 2014

22/225



20022009 Sub-Investigator: XTL Pharmaceuticals grant. A pilot phase II,multi-center, randomized, double-blind, placebo-controlled, doseescalation Study of the Safety and Efficacy of Human HCV-antibody (HCV-AB 68) for Prevention of Hepatitis C DiseaseRecurrence in Patients who have Received Hepatic Allografts forTreatment of End-stage Liver Disease due to Hepatitis C VirusInfection. Grant award: $10,000.

20032004 Principle Investigator: Bristol-Meyers Squibb. Entecavir vs. Lamiv-udine (52 weeks therapy) in Adult patients with Chronic HepatitisB who have had an Incomplete Response to Lamivudine Therapy:Rollover study.

2003 Sub-investigator: Medtronic grant. Interstim sacral nervestimulation therapy for bowel control: Fecal incontinence study.

2003 Principle Investigator: Roche Pharmaceuticals grant. Randomized,open-label study of Pegasys and Epivir-HBV as initial treatment ofHBeAg negative HBV.

2003 Sub-investigator: Two-week randomized, double-blind, placebo-controlled study of PRN, BID and fixed dosing regimens ofalosetron in female subjects with severe diarrhea-predominantirritable bowel syndrome who have failed conventional therapy.

2003 Principle Investigator: Idun Pharmaceuticals grant. Caspase studyfor the treatment of chronic liver disease including chronic HCV

infection.

2003 Principle Investigator: United Therapeutics grant. Phase II study ofUT 231, including PK assessment, in patients with chronic HCVwho were non-responders to previous interferon and ribavirintherapy.

2003 Principle Investigator: Actelion Pharmaceuticals. Phase II Studyof tezosentan for the treatment of portal hypertension.

2003 SubInvestigator: Celera grant. Natural history of fibrosis inpatients who had undergone treatment for HCV.

20032004 Principle Investigator: Chiron grant. Evaluation of the ProcleixHIV-1/HCV RNA qualitative assay in detecting HCV RNA fromwhole blood from HCV infected patients.

5/21/2018 Gish CV July 23 2014

23/225



20032006 Sub-Investigator: Hoffman-LaRoche grant. Rrandomized, multi-center, open-label, phase IV study evaluating efficacy and safetyof 16 week vs. 24 week treatment with Pegasys in combinationwith Copegus in interferon-nave patients with chronic hepatitis Cgenotype 2 or 3 virus infection. Grant award: $136,513.

20032006 Principle Investigator: Gilead Pharmaceuticals grant. Long-termstudy of durability of seroconversion in patients with chronichepatitis B virus infection who have seroconverted whileparticipating in the previous Gilead-sponsored study of adefovirdipivoxil. Grant award: $1,000.

20032005 Principle Investigator: Celera grant. DNA genotyping and mRNA profilingof newly recruited, treatment-nave HCV patients.

Grant award: $120,300.

20032004 Principle Investigator: XTL Pharmaceuticals grant. Phase II, multi-center, randomized, open-label, dose ranging, parallel group studyof the antiviral effects, pharmacokinetics and safety of HepeX-Bas compared to hepatitis B immune globulin in patients who havereceived hepatic allografts for hepatitis B virus infection.Grant award: $7,400.

2004 Principle investigator (CPMC): Amgen grant. Treatment ofribavirin-induced anemia during the treatment of chronic HCV withdarbopoietin (ADHERENCE trial).

2004 Principle investigator: (CPMC) Ortho Biotech grant. Prospectivetreatment trial using erythropoietin to treat anemia due to ribavirinduring interferon treatment for chronic HCV infection.

2004 Principle Investigator: Eximias Pharmaceutical Corp. grant.Phase III Evaluation of THYMITAQ(R) nolatrexed dihydrochloride,in unresectable hepatocellular carcinoma (ETHECC[C]) trial.

2004 Co-Principle Investigator: WEAVE (WEST EAST ANTIVIRALEFFICACY) protocol- Randomized trial of Pegasys/ribavirin vs.Pegasys/ribavirin and CAM therapy.

20042005 Principle Investigator: Idun Pharmaceuticals grant. A phase IIIdose-response study of caspase inhibitor in hepatitis C patients.Grant award: $62,100.

20042005 Sub-Investigator: Boehringer Ingleheim grant. A pharmacokineticstudy to assess nevirapine levels in HIV-infected patients withimpaired hepatic function. Grant award: $19,929.

5/21/2018 Gish CV July 23 2014

24/225



20042006 Sub-Principle Investigator: Ortho Biotech grant. Procrit for thetreatment of post-transplant anemia. Grant award: $50,000.

20042006 Principle Investigator: eXagen Diagnostics grant. Identification of amolecular signature from peripheral blood that predicts interferonresponse in hepatitis C infection. Grant award: $30,000.

20042006 Sub-Investigator: Hoffman-LaRoche grant. Prospective,randomized, multi-center, open-label, comparative safety andefficacy study of prophylactically administered pegylated interferonplus ribavirin vs. no prophylaxis following liver transplantation forhepatitis C. Grant award: $246,608.

20042007 Principle Investigator: Valeant Pharmaceuticals grant. Phase IIrandomized, double-blind, multi-center study to compare safetyand efficacy of viramidine to ribarivin in treatment-nave patientswith chronic hepatitis C. Grant award: $202,395.

20042007 Sub-Investigator: Vertex Pharmaceuticals grant. Phase 2b studyof merimepodib in combination with interferon and ribavirin insubjects with chronic hepatitis C genotype 1 non-responsive toprior therapy and interferon. Grant award: $96,740.

20042009 Co-Investigator: NIH grant. Early detection of liver cancer.Grant award: $50,694.

20052007 Principle Investigator: Stanford University grant. CPMC/Stanford

keratin study of liver disease in African Americans.Grant award: $2,000.

20052007 Sub-Investigator: Idenix Pharmaceuticals grant. A randomized,double blind trial of telbivudine vs. adefovir dipivoxil in adults withHBeAg-positive, compensated chronic hepatitis B.Grant award: $28,380.

20052008 Sub-Investigator: Idenix Pharmaceuticals grant. Open-label studyof telbivudine in adults with chronic hepatitis B previously treatedin Idenix-sponsored telbivudine studies. Grant award: $126,005.

20052007 Sub-Investigator: Idenix Pharmaceuticals grant. Randomized,phase IIb clinical trial to evaluate the safety and antiviral activity ofNM283 and the combination of interferon plus NM283 in patientswith chronic hepatitis C who have previously failed to respond tostandard therapy. Grant award: $69,883.

5/21/2018 Gish CV July 23 2014

25/225



2005 Sub-Investigator: Hemolife Medical grant. Continuous plasmafiltration with sorbent adsorbent detoxification utilizing theHemoLife Medical Inc. HLM 100 column and the HLM-200 plasmafilter for the treatment of episodic type C hepatic encephalopathyin subjects with decompensated cirrhosis. Grant award: $86,790.

2005 Sub-Investigator: Orphan Therapeutics grant. A double-blind,randomized, placebo-controlled, multi-center phase III study ofintravenous terlipressin in patients with hepatorenal syndromeType 1. Grant award: $34,791.

20072008 Principle investigator: Nucleonics siRNA therapy for the treatmentof chronic hepatitis B. Grant award: $124,000.

20082010 PROTOCOL GS-US-174-0108 A Phase II, Double-Blind, Multi-Center, Randomized Study Comparing Tenofovir DisoproxilFumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, andEntecavir In The Treatment Of Chronic Hepatitis B Subjects WithDecompensated Liver Disease And In The Prevention Of HepatitisB Recurrence Post-Transplantation.Budget $26,642

2010 Sub-Investigator: Study of the Antiviral Activity of Entecavir inPatients Receiving Liver Transplant Due to Chronic Hepatitis BVirus Infection.

2010 Sub-Investigator: Ph 2 rollover protocol of Telaprevir (VX-950) incombination with Peginterferon Alfa-2a and Ribavirin in subjects

enrolled in the controlled group (Group A) of study VX06-950-106,VX05-950-104 and VX05-650-104EU who did not achieve ormaintain an undetectable HCV RNA level through sustained viralresponse.

2010 Sub-Investigator: A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir inRenal Transplant Recipients with BK Virus Nephropathy(CASG209).

2010 Sub-Investigator: Multicenter, randomized, double-blind, placebocontrolled, multiple dose study of the safety, tolerability and

population pharmacokinetics of CMX001 in post transplantsubjects with BK virus viruria.

2010 Sub-Investigator: A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment forhepatocellular carcinoma after surgical resection or local ablation.

5/21/2018 Gish CV July 23 2014

26/225



2010 Sub-Investigator: A Phase II randomized, double-blind, placebo-controlled study of Sorafenib or Placebo in combination withtransarterial chemoembolization (TACE) performed with DC beadand doxorubicin for intermediate stage hepatocellular carcimoma(HCC).

2010 Principle-Investigator: A Randomized, Double-blind, Multi-centerPhase II Study of Brivanib plus Best Supportive Care (BCD)versus Placebo plus BSC in Subjects with AdvancedHepatocellular Carcinoma (HCC) who have Failed or areIntolerant to Sorafenib. Budget amount $244,105.00

2010 Sub-Investigator: A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokineticsof GC33 in Combination with Sorafenib (Nexavar) in Patients with

Advanced or Metastic Hepatocellular Carcinoma (HCC).

2010 Sub-Investigator: Global Investigation of Therapeutic Decisions inHepatocellular Carcinoma and of its Treatment with Sorafenib.

2010 Principle-Investigator: Randomized, Controlled Phase 2a/b Studyof the Efficacy and Safety of PEG-rIL-29 Administed inCombination with Ribavirin to Treatment-Nave Subjects withChronic Hepatitis C Virus Infection. Budget $48,950.00

2010 Sub-Investigator: A Rollover Protocol to Provide Open-LabelEmtricitabine/Tenofovir Disoproxil Fumarate Combination Product

to Subjects Completing the GS-US-203-0107 Study.

2010 Principle-Investigator: A Phase 2, Randomized, Double-BlindStudy Exploring the Efficacy, Safety and Tolerability of TenofovirDisoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plusTenofovir DF Fixed-Dose Combination Therapy in SubjectsCurrently Being Treated with Adefovir Dipiivoxil for ChronicHepatitis B and having Persistent Viral Replication.

2010 Sub-Investigator: An Open Label Trial of Telbivudine (LdT) inAdults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies. NV-02B-022.

2010 Sub-Investigator: A Phase 2, Open-Label, Multi-Center,Randomized Trial to Demonstrate the Pharmacokinetics of LCP-TACRO Tablets Once Daily and Program Capsules Twice Daily in

Adult De Novo Liver Transplant Patients.

5/21/2018 Gish CV July 23 2014

27/225



2010 Sub-Investigator: A Phase 2, Randomized, Double-Blind,Multicenter, Dose and Duration Finding Study to Evaluate theSustained Virologic Response of the HCV Polymerase InhibitorProdrug (RO5024048) in Combination with Pegasys and Copegusversus the Currently Approved Combination of Pegasys andCopegus in Treatment Nave Patients with Chronic Hepatitis CGenotype 1 or 4 Virus Infection.

2010 Sub-Investigator: Salix Pharmaceuticals, Inc./A Multi-Center,Open-Label, Trial to Evaluate the Long-Term Safety andTolerability of Rifaximin 550 BID in Subjects with a History ofHepatic Encephalopathy.

2010 Sub-Investigator: Long-Term Follow-Up of Subjects in a Phase 2or 3 Clinical Trial in which SCH 503034 was Administered for theTreatment of Chronic Hepatitis C.

2010 Sub-Investigator: Ph2, Open label randomized study to evaluatethe efficacy and safety of the combination product,Emtricitabine/Tenofovir (Truvada) in the presence of absence ofHepatitis B immunoglobulin (CHB) post-orthotopic liver transplant(OLT).

2010 Sub-Investigator: An open-level, single-arm, roll-over trial oftelaprevir in combination with pegylated interferon alfa-2a(Pegasys) and ribavirin (Copegus) for subjects from the controlgroup of the VX-950-TiDP24-C216 trail who failed therapy for

virologic reasons.

2010 Sub-Investigator: Phase III, 24 dose regimens of Telaprevir incombination with Peginterferon alfa 2a and Ribavirin in treatmentnave subjects with genotype 1 chronic hepatitis C.

2010 Sub-Investigator: Randomized study of stopping treatment at24wks vs. continuing treatment to 48 weeks in treatment-navesubjects with Genotype 1 CHC who achieve an extended RVRwhile receiving Telaprevir, Peginterferon (Peasys) and Ribavirin(Copegus).

2010 Sub-Investigator: A 3-Year, Virology Follow up Study in SubjectsPreviously Treated WithTelaprevir in Select Clinical Studies.

2010 Sub-Investigator: Efficacy and Safety of the Extracorporeal LiverAssist Device (ELAD) in Subjects with Fulminant Hepatic Failure(FHF).

5/21/2018 Gish CV July 23 2014

28/225



2010 Sub-Investigator: Efficacy and Safety of the Extravorporeal LiverAssist Device (ELAD) in Subjects with Acute on Chronic Hepatitis(AOCH).

2010 Sub-Investigator: A multi-center randomized, double-blind,placebo-controlled trial to evaluate the efficacy, safety andtolerability of Rifaximin 550 mg bid for 6 months in preventinghepatic encephalopaty.

2010 ILCS Horizon Scanning Protocol International and NationalPriorities for Liver Cancer Control.Johns Hopkins BloombergSchool of Public Health IRB.

4/20108/2013 Co-Primary Investigator: NV20536. A Roche Study: A Random-ized, Double-blinded, Multicenter, Dose and Duration FindingStudy to Evaluate the Sustained Virologic Response of the HCVPolymerase Inhibitor Prodrug (RO5024048) in Combination withPegasys and Copegus versus the Currently Approved Combi-nation of Pegasys and Copegus in Treatment-Naive Patientswith Chronic Hepatitis C Genotype 1 or 4 Virus Infection. Grant

Award: $214,336.60.

11/20108/2013 Co-Primary Investigator: NV22688. A Roche Study: A Long-TermMonitoring Study To Evaluate The Persistence Of Direct Acting

Antiviral (DAA) Treatment-Resistant Mutations Or The DurabilityOf Sustained Virological Response (SVR) In Patients TreatedWith DAA-Containing Regimens For Chronic Hepatitis C Infection

(CHC). Grant Award: $21,273.00.

4/20118/2013 Co-Primary Investigator: P7977-0724. A Gilead Sciences &Pharmasett study: A Multicenter, Open-label, Randomized, Dura-tion Finding Study to Investigate the Safety, Tolerability, Pharma-cokinetics and Pharmacodynamics following Oral Administrationof PSI-7977 in Combination with Pegylated Interferon and Ribavi-rin in Treatment-Nave Patients with Chronic HCV Infection Geno-type 1,4,5, or 6. Grant Award: $117,872.

2011 Co-Primary Investigator: WV21913C. A Roche Study: A Random-ized, Open-Label, Multicenter Study to Evaluate the Sustained Vi-

rologic Response of the HCV Protease Inhibitor DanoprevirBoosted with Low Dose Ritonavir (DNV/r) and Copegus, in Com-bination with the HCV Polymerase Inhibitor Prodrug RO 5024048and/or Pegasys in Chronic Hepatitis C Genotype 1 Patients whohave Failed a Previous Course of Peginterferon Alfa Plus Ribavi-rin Combination Therapy. Grant Award: $141,986.

5/21/2018 Gish CV July 23 2014

29/225



6/20118/2013 Co-Primary Investigator: GS-US-248-0120. A Gilead Sciences,Inc. Study: A Phase 2 Randomized, Open-Label Study of GS-

5885 Administered Concomitantly with GS-9451, Tegobuvir andRibavirin (RBV) to Treatment-Naive Subjects with Chronic Geno-type 1 HCV Infection. Grant Award: $213,102.

9/20118/2013 Co-Primary Investigator: GS-US-248-0121. A Gilead Sciences,Inc. Study: A Phase 2 Randomized, Open-Label, Exploratory Trialof GS-5885, GS-9451 with Peginterferon Alfa 2a (PEG) and Rib-avirin (RBV) in Treatment-Nave Subjects with Chronic Genotype1 Hepatitis C Virus Infection and IL28B CC Genotype. Grant

Award: $59,742.

20118/2013 Primary Investigator: BIPI 1220.48. A Boehringer IngelheimStudy: A Phase III, open-label study of once daily BI 201335 240mg for 24 weeks in combination with pegylated interferon-a(PegIFN) and ribavirin (RBV) in patients with genotype 1 chronichepatitis C infection who failed a prior PegIFN / RBV treatment[Version 3.0] Grant Award: $89,739.

20118/2013 Co-Primary Investigator: AI444038. A Bristol-Myers Squibb Study:Open-Label, Single Arm Evaluation of BMS-790052 in Combina-tion with Peg-Interferon Alfa-2a and Ribavirin in Black-African

Americans, Latinos, and White-Caucasians with Chronic HepatitisC Genotype 1 Infection. Grant Award: $92,572.

20118/2013 Co-Primary Investigator: GS-US-248-0123. A Gilead Sciences,Inc. Study: A Long Term Follow-up Registry Study of SubjectsWho Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection.Grant Award: $33,491.

20118/2013 Co-Primary Investigator: GS-US-248-0122 . A Gilead Sciences,Inc. Study: A Long Term Follow-up Registry for Subjects Who

Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection.Grant Award: $33,491.

20118/2013 Co-Primary Investigator: NV27779. A Roche Study: A Phase II,Randomized, Double-Blind, Multicenter, Parallel Group Study ToEvaluate The Sustained Virologic Response Of The HCV Poly-merase Inhibitor Prodrug Ro5024048 In Combination WithTelaprevir And Pegasys/Copegus In Patients With ChronicHepatitis C Genotype 1 Virus Infection Who Were Prior Null Re-sponders To Treatment With Pegylated Interferon/Ribavirin.Grant Award: $95,089.

5/21/2018 Gish CV July 23 2014

30/225



20118/2013 Primary Investigator: P2938-0721. A Gilead Sciences / Pharma-sett, Inc. Study: An International, Multi-center, Blinded, Random-

ized Study to Investigate Safety, Tolerability, Pharmacokineticsand Pharmacodynamics following Administration of RegimensContaining PSI-352938, PSI-7977, and Ribavirin in Patients withChronic HCV Infection. Grant Award: $273,564.

20128/2013 Primary Investigator: BMS AI444-043. A Brstol-Myers SquibStudy: A Phase 3, Open Label Study of Safety and Efficacy withBMS-790052 plus Peg- Interferon Alfa 2a and Ribavirin in Previ-ously Untreated HCV Patients Coinfected with Human Immunode-ficiency Virus (HIV) and Hepatitis C Virus (HCV). Grant Award:$73,976.

20128/2013 Co-Primary Investigator: VX11-950-114. A Vertex Study: A Phase3b Study of 2 Treatment Durations of Telaprevir, PEG-INF (Pega-sys), and Ribavirin (Copegus) in Treatment-Naive and PriorRelapser Subjects with Genotype 1 Chronic Hepatitis C and IL28BCC Genotype [Version 2.0]. Grant Award: $58,092.

20128/2013 Co-Primary Investigator: P7977-2025. A Gilead Sciences / Phar-masett, Inc. Study: An Open-Label Study to Explore the ClinicalEfficacy of GS-7977 with Ribavirin Administered Pre-Transplant inPreventing Hepatitis C Virus (HCV) Recurrence Post-Transplant.Grant Award: $80,722.

20128/2013 Co-Primary Investigator: GS-US-334-0107 . A Gilead Sciences,Inc. Study: A Phase 3, Multicenter, Randomized, Double-Blind,Placebo-Controlled Study to Investigate the Efficacy and Safety ofGS-7977 + Ribavirin for 12 Weeks in Subjects with Chronic Geno-type 2 or 3 HCV Infection who are Interferon Intolerant, InterferonIneligible or Unwilling to Take Interferon. Grant Award: $102,037.

20128/2013 Co-Primary Investigator: GS-US-334-0109, A Gilead Sciences,Inc. Study: An Open-Label Study of GS-7977+ Ribavirin with orwithout Peginterferon Alfa-2a in Subjects with Chronic HCV Infec-tion who Participated in Prior Gilead HCV Studies Grant Award:$94,440.

20128/2013 Co-Primary Investigator: GS-US-334-0108, A Gilead Sciences,Inc. Study: A Phase 3, Multicenter, Randomized, Double-Blind,Study to Investigate the Efficacy and Safety of GS-7977 + Ribavi-rin for 12 or 16 Weeks in Treatment Experienced Subjects withChronic Genotype 2 or 3 HCV Infection. Grant Award: $100,831.

5/21/2018 Gish CV July 23 2014

31/225



20128/2013 Primary Investigator: P7977-1231, A Gilead Sciences / Pharma-sett, Inc. Study: A Phase 3, Multicenter, Randomized, Active-

Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interfer-on and Ribavirin for 24 Weeks in Treatment-Nave Patients withChronic Genotype 2 or 3 HCV Infection. Grant Award: $43,041.

20128/2013 Primary Investigator: GS-US-283-0102, A Gilead Sciences, Inc.Study: A Double-Blind, Randomized, Placebo-Controlled, Singleand Multiple-Dose Ranging, Study Evaluating the Safety, Tolera-bility, Pharmacokinetics, Pharmacodynamics, and Antiviral Activityof GS-9620 in Virologically Suppressed Subjects with ChronicHepatitis B Virus Infection. Grant Award: $43,041.

2012 Primary Investigator: GS-US-283-0106, A Gilead Sciences, Inc.Study: A Double-Blind, Randomized, Placebo-Controlled, Singleand Multiple-Dose Ranging, Adaptive Study Evaluating the Safety,Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral

Activity of GS-9620 in Treatment Naive Subjects with ChronicHepatitis B Virus Infection. Grant Award: $178,385. 6/1/128/2013.

2012 Primary Investigator: GS-US-243-0102., A Gilead Sciences, Inc.Study: A Double-Blind, Randomized, Placebo-Controlled, Singleand Multiple-Dose Ranging Study Evaluating the Safety, Tolerabil-ity, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity ofGS-9620 in Treatment Nave Subjects with Chronic Hepatitis C Vi-rus Infection. Grant Award: $183,441. 6/1/128/2013.

2012 Primary Investigator: GS-US-283-0110, A Gilead Sciences, Inc.Study: A Long Term Follow-up Registry Study of Subjects WhoDid Not Achieve Loss of S Antigen (HBsAg) and Sustained HBVViral Load Reduction Below the Limit of Quantitation (BLQ) in Gil-ead-Sponsored Trials of GS-9620 in Subjects with Chronic Hepati-tis B Infection. Grant Award: $139,400. 7/1/128/2013.

2012 Co-Primary Investigator: GS-US-334-0110, A Gilead Sciences,Inc. Study: A Phase 3, Multicenter, Open-Label Study to Investi-gate the Efficacy and Safety of GS-7977 with Peginterferon Alfa2aand Ribavirin for 12 Weeks in Treatment-Naive Subjects withChronic Genotype 1, 4, 5, or 6 HCV Infection. Grant Award:$102,411. 7/1/128/2013.

5/21/2018 Gish CV July 23 2014

32/225



2013 Co-Primary Investigator: GS-US-337-0109, A Gilead Sciences,Inc. Study: A Phase 3, Multicenter, Randomized, Open-Label

Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination Ribavirin for 12 and 24 Weeks inTreatment-Experienced Subjects with Chronic Genotype 1 HCVInfection. Gilead Sciences, Inc. Grant Award: $116,799. 1/1/138/2013.

2013 Co-Primary Investigator: GS M14-002. An AbbVie Study: A Ran-domized, Double-Blind, Controlled Study to Evaluate the Efficacyand Safety of the Combination of ABT-450/Ritonavir/ABT-267(ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin(RBV) in Treatment-Nave Adults with Genotype 1a Chronic Hepa-titis C Virus (HCV) Infection (PEARL-IV). Grant Award:$126,539.00. 3/1/138/2013.

2013 Co-Primary Investigator: GS-US-337-0108, A Gilead Sciences,Inc. Study: A Phase 3, Multicenter, Randomized, Open-LabelStudy to Investigate the Efficacy and Safety of Sofosbuvir / Ledi-pasvir Fixed-Dose Combination Ribavirin for 8 Weeks andSofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks inTreatment-Nave Subjects with Chronic Genotype 1 HCV Infec-tion. Grant Award: $104,650. 5/1/138/2013.

2013 GS-US-342-0102, A Gilead Sciences, Inc. Study: A Phase 2, Mul-ticenter, Randomized, Open-Label Study to Investigate the Safetyand Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Nave Subjects with Chronic HCV Infection . Grant Award:$46,551. 5/1/138/2013.

5/21/2018 Gish CV July 23 2014

33/225


UCSD: RESEARCH / ADVISORY

2012 Co-Principal Investigator: Biological Markers and Outcomes inHepatitis C and Other Liver Diseases. All UCSD Health Systems.Other Co-Principal Investigator: Julio Gutierrez, MD.

2013 Co-Principal Investigator: STOPC Biobank Genetics Consortium(UCSD Unit). Other Co-Principal Investigator: Alexander Kuo,MD.

2012 Principal Investigator: Retrospective Analysis of UCSD Liver Pa-tient Population,UCSD Medical Center, 5-Year Study. UCSDLiver Center.

2011 Principal Investigator: POC Hepatitis B and Hepatitis C:Screening for Viral Hepatitis, Its Role in Linkage to Care andEconomic Ramification in Healthcare,Asian Pacific HealthFoundation (APHF) Community Outreach Events. In Process.

2011 Principal Investigator: Retrospective Analysis of UCSD LiverPatient Population. UCSD Human Research ProtectionsProgram. UCSD Medical Center. Study is for 5 years,In Process.

20112013 Principal Investigator: UCSD Liver Research Biorepository.UCSD Health Systems.

2012 Principal Investigator: An International Multi-Center, Blinded,Randomized Study to Investigate Safety, Tolerability, PK and PDFollowing Administration of Regimens Containing PSI-352938,

PSE-7977, and Ribavirin in Patients with Chronic HCV, AVRC atUCSD.

20122013 Principal Investigator: Barriers to Hepatitis B Screening andHepatitis B Knowledge Among Asian Population in San DiegoCounty. All UCSD Health Systems.

20122013 Study to Improve Early Identification of Hepatitis B (HBV) and C(HCV) Infections in Clinical and Community Settings and to En-hance Linkage to Care, Treatment, and Preventive Services for In-fected Persons. Grant submitted by Hepatitis Free San Diego incollaboration with the Antiviral Research Center, University ofCalifornia, San Diego. Approved by Centers for Disease Control

and Prevention (CDC), September 2012 for 1 year.

2013 Present Co-investigator: A University of California, San Diego SkaggsSchool of Pharmacy and Pharmaceutical Sciences study; Cost-Effectiveness of Hepatitis C Screening: Point of Care (POC) vs.Standard of Care Tests.

5/21/2018 Gish CV July 23 2014

34/225


UCSD: RESEARCH / ADVISORY:Continued

2012Present Co-investigator: A University of California, San Diego SkaggsSchool of Pharmacy and Pharmaceutical Sciences study. Cost Ef-ficiency Analysis of Point-of-Care versus Standard of Care Testsfor Hepatitis B in Asian Americans in San Diego County.

8/31/2013 Robert G. Gish MDPresent Robert G. Gish Consultants, LLC

Business address:6022 La Jolla Mesa DriveSan Diego, CA 92037Cell phone: 1 858 229 9865Email: [email protected]: robertgish.com

COINVESTIGATOR: GASTROINTESTINAL TRIALS

2002 Tegaserod vs. Placebo, for functional dyspepsia with documenteddelayed gastric emptying. (Novartis).

2002 A phase III, double-blind, multicenter, randomized, placebo-controlled study of the effects of a somatostatin analogue -lanreotide as an adjuvant to endoscopic band ligation of patientswith acute bleeding from oesophageal varies secondary tocirrhosis and portal hypertension (Biomeasure).

2002 Performance evaluation of the given diagnostic imaging system inthe upper gastrointestinal tract (given imaging).

2002 An efficacy and safety study of intravenous pantoprazole in theprevention of recurrent peptic ulcer bleeding after successfulhemostasis (Wyeth-Ayerst).

2002 Prospective comparison of air contrast barium enema (ACBE)computed tomographic colonography (virtual colonoscopy) andcolonoscopy for evaluation of the colon.

2002 Evaluation of investigational sclerotherapy-type needle for tissueidentification (Enterics).

2002 A pilot Phase II, muliticenter, randomized, double-blind, placebo-controlled, dose escalation study of the safety and efficacy ofhuman HCV-antibody (HCV-Ab XTL 68) for prevention of hepatitisC disease recurrence in patients who have received hepaticallografts for treatment of end-stage liver disease due to hepatitisC virus infection.

5/21/2018 Gish CV July 23 2014

35/225


COINVESTIGATOR: GASTROINTESTINAL TRIALS: Continued

2010 Moving towards comprehensive liver cancer control: A qualitativestudy.

2010 Applying conjoint analysis to develop a comprehensive livercancer control plan in Asia.

2011 Predicting the future impact of emerging technologies onHepatocellular carcinoma (HCC): Measuring stakeholderspreferences with best-worst scaling.

2011 Stakeholder involvement in priority setting of strategies to improvehepatocellular carcinoma policy (EU data).

2011 Predicting the future impact of emerging technologies onHepatocellular carcinoma (HCC): Measuring stakeholders

preferences with best-worst scaling.

2011 Predicting the future impact of emerging technologies onhepatocellular carcinoma (HCC): Using best-worst scaling toexplore clinicians views.

2011 Controlling liver cancer internationally: A qualitative study ofclinicians perceptions of current public policy needs.

2011 Stakeholder involvement in priority setting of strategies to improveliver cancer control policy in Asia.

2011 Focus will be all Asian data results vs. USA - performance needsand discussion around country-level differences (possiblepublication in special supplement of ONCOLOGY, tbc).

2011 Evaluation of the Merits of the Evidence Regarding theIdentification of Hepatitis C Virus (HCV) and HCV-Related ChronicDisease Among Persons Born from 1945 to 1965.

2012 Associate Member, Moores UCSD Cancer Center.

2013 Editorial Advisory Board, Gastroenterology & Hepatology Journal,Digestive Disease Week Breakfast, Orlando, FL.; May 19, 2013.

20112013 STOPSC Genetics Recruitment; Studies of Primary SclerosingCholangitis (STOPSC) is a multi-center joining effort tounderstand the possible causes and treatment of PrimarySlerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) aswell as the effects of the disease on the liver over time

5/21/2018 Gish CV July 23 2014

36/225


TEACHING ACTIVITIES

19871988 Consult AttendingGastroenterology and Liver ServicesWadsworth Veterans Hospital

Los Angeles, California

19871988 Clinical ToxicologyUCLA School of MedicineLos Angeles, California

19891991 UC Davis Liver ConferenceMartinez VA, University of California, DavisMartinez, California

19911995 Gastroenterology and Liver ClinicUniversity of California, DavisSacramento, California

1994 Visiting ProfessorUniversity of FloridaGainesville, Florida

1996 Visiting ProfessorUniversity of IowaIowa

1996, 1997 & 2003 Visiting ProfessorUniversity of California, Los AngelesLos Angeles, CA

2003 Visiting ProfessorUniversity of ColoradoDenver, Colorado

2006 Visiting ProfessorUniversity of Southern CaliforniaLos Angeles, California

19882010 Gastroenterology Teaching ServiceHighland General Hospital, Alameda County Medical CenterOakland, California

19882010 Gastroenterology and Liver Teaching Service

California Pacific Medical CenterSan Francisco, California

19931999 Merced Community HospitalTeaching FacultyFamily Medicine ProgramMerced, CaliforniaUniversity of California, DavisSacramento, California

5/21/2018 Gish CV July 23 2014

37/225


TEACHING ACTIVITIES: Continued

19962010 Department of MedicineUniversity of California, San FranciscoSan Francisco, California

OSCE 1995-2002Medicine Teaching Service at CPMCHousestaff Teaching Service at Highland Hospital50 hours per year of teaching service (minimum)

20082010 Department of MedicineUniversity of California, San FranciscoSan Francisco, CaliforniaMedicine Teaching Service(a total of 88 hours of preceptorship)

20102013 Department of Medicine

University of California, San DiegoSan Diego, California

2013 Consultant to Hepatitis Free San Diego Elective Course,UCSD Skaggs School of Pharmacy and PharmaceuticalSciences, San Diego, California

2013 Developed and Funded New Graduate Training ProgramCommittee approval for Transplant Hepatology fellow for oneyear, Dr. Heather Patton,Department of Medicine, University of California, San DiegoSan Diego, California

June 2013 Review of Dr. Tami Daugherty for Clinical Associate ProfessorDepartment of Medicine, Stanford University School of Medicine,Division of Gastroenterology and HepatologyStanford, California

COMMITTEES

19891992 Member, Human Liver Cell Culture FacilitySRI InternationalMenlo Park, California

19891992 Member, Executive CommitteePacific Transplant InstituteSan Francisco, California

19901992 Executive Vice President, S.F. Bay Area ChapterAmerican Liver FoundationSan Francisco, California

5/21/2018 Gish CV July 23 2014

38/225


COMMITTEES:Continued

19901992 Chairman, Fundraising CommitteeS.F. Bay Area Chapter

American Liver Foundation

San Francisco, California

19911993 Member, Scientific Exhibits CommitteeAmerican Society for Gastrointestinal Endoscopy

19921993 Chairman, Nominating committeeS.F. Bay Area Chapter

American Liver FoundationSan Francisco, California

19921993 Chairman, Public Education CommitteeS.F. Bay Area Chapter


1993 Member, Committee for Test Question DevelopmentAmerican Board of Internal Medicine

19931996 Chairman, Medical Advisory CommitteeS.F. Bay Area Chapter


19941997 Member, Committee on Liver and Intra-abdominal Organ

TransplantationAmerican Society of Transplant Physicians

1996 Member, Abstract Review CommitteeAmerican Society of Transplant Physicians

19971998 Member, Hepatitis Task ForceState of California Public Awareness and Department ofCorrections, under direction of Senator Polanco

19972001 Member, Clinical Research CommitteeAmerican Association for the Study of Liver Diseases

1999 SecretaryHepatitis Resource Network

19992000 Chairman, Search CommitteeCalifornia Pacific Medical Center PathologistSan Francisco, CA

5/21/2018 Gish CV July 23 2014

39/225



19992013 Member, Governing CouncilAbstract ReviewerAmerican Association for the Study of Liver Diseases (AASLD)

19992001 Co-Chair, Membership CommitteeAmerican Society of Transplantation

20012002 Medical Adivsory CommitteeAmerican Liver FoundationSan Francisco, California

20012002 Member, HCV Advocate Medical Writers Circle

20022004 Member, Abstract Review CommitteeAASLD

2003 ChairAASLD Topic Forum

2003 Faculty MemberAASLD Expert Consensus Conference

2003 Task Force MemberSanta Barbara County HCV Strategic Plan

20032006 Member, Liver and Intestinal Transplantation CommitteeOrgan Procurement and Transplantation Network (OPTN)/UNOS

2004 Member, Health Liver Alert Screening CommitteeAmerican Liver Foundation

2004 Expert Council MemberAdvancing Clinical Treatment of Hepatitis B Virus (ACT-HBV) Ini-tiative

20042006 Member, Fund Development CommitteeAASLD

20052007 Member, Public Policy Committee

AASLD

20042010 Member, Research Development CommitteeCalifornia Pacific Medical Center

2006Present Member, Scientific CommitteeHep Dart Conference

5/21/2018 Gish CV July 23 2014

40/225



19942007 Director, Department of TransplantationSerum and Tissue BankCalifornia Pacific Medical Center

19952007 Liver Center MemberUniversity of California, San Francisco

19961998 Member, National Scientific Review CommitteeAmerican Liver Foundation

19972000 Member, Membership CommitteeAmerican Society of Transplant Physicians

19972003 Medical Review SubcommitteeAmerican Liver Foundation

1997 Member, Southern China Hepatitis Study GroupGuangzhou, China and Hong Kong

19982010 Member, Committee on Information TechnologyCalifornia Pacific Medical CenterSan Francisco, California

20042005 Member, Hepatitis Plan WorkgroupState of Nevada

2007 Member, Fund Raising Study Task Force

AASLD

2007 Abstract ReviewerAmerican Transplant Congress

20072008 Member, Organizing CommitteeHong Kong-Shanghai International Liver Congress

20072010 San Francisco Hep B Free Campaign

20082010 Board Member, American Liver Foundation, San FranciscoChapter

20082010 Advisor, LASHLocal Area Support for Hepatitis, Inc. (L.A.S.H.)

2008Present Board Member, FAIR Foundation

2008Present Scientific Advisory Committee, Global Antiviral Journal

5/21/2018 Gish CV July 23 2014

41/225



2009 Program of comprehensive research actions: Hepatocellular car-cinoma. French National Cancer Institute. Grant Review. 2009

20092010 Member at large, Nominating CommitteeAmerican Society of Transplantation (AST)

2009Present Board MemberHepatitis C Oversight Partnership (HepCop)

2009Present Group Membership, AASLDSpecial Interest Group on Hepatitis B (SIG)

2010Present Scientific Board MemberAsian Pacific Association for the Study of Liver Disease (APASL)

2010 Abstract ReviewerAsian Pacific Association for the Study of Liver Disease(ASPASL), Beijing, China

20092013 Co-Chair of and Memberof Steering CommitteeAASLD Hepatitis B Special Interest Group (SIG)

2010 Nomination CommitteeSan Francisco Medical Society

2010Present Member, Hepatitis D International Network

2011Present LI-RADS(Liver Imaging Reporting and Data System)

2011 Abstract review panel: AASLD Fall meeting

2011Present San Diego County Medical Society

2011Present Member, Philippines Viral Hepatitis Project

20122013 Graduate Medical Education Enrollment Committee, TransplantHepatology Program University of California, San Diego.

2012Present Member, International Coalition of Hepatology Educators

2012 Abstract Review Committee, American Association for the Studyof Liver Disease

20122013 Vice President, Steering committee of the National Viral HepatitisRound Table

20122015 Member, National Viral Hepatitis Round Table

5/21/2018 Gish CV July 23 2014

42/225



2012Present Member, Coalition to Eradicate Viral Hepatitis in Asia Pacific(CEVHAP)

2011 & 2012 Faculty Interviewer Committee, Internal Medicine Residency Ap-plicants, University of California, San Diego Department of InternalMedicine.

2013 AASLD Abstract Review Committee

2013 Member, Editorial Advisory Board, Gastroenterology & HepatologyJournal, Digestive Disease Week Breakfast, Orlando, FL.,May 19, 2013.

20112013 EMR Provider Optimization Group (POG) EPIC Commitee

2013 Planning and Steering Committee Member for Imaging andSurveillance, Liver Cancer Roundtable

2013 Executive Vice-Chair, National Viral Hepatitis RoundtableCommittee

2013Present Founding Member, Liver Cancer Roundtable

2010 Co-Chair, the 2ndBiannual International Conference of ArmenianHepatological Forum.

2013 Finance Review Committee, American Association for the Study

of Liver Diseases (AASLD), Annual Business Meeting

2014 Committee Member Nominee, Centers for Disease Control andPrevention (CDC)/HRSA Advisory Committee on HIV, ViralHepatitis and STD Prevention and Treatment (CHACHSPT).

2014Present Medical DirectorHepatitis B Foundation, Doylestown, PA

2014Present MemberGlobal Hepatitis Community,www.hepcomm.com

2014Present Vice President & Member, Board of DirectorsFAIR Foundation, Palm Desert, CA

2014Present Chair, Safety Monitoring Board ReviewNovira Therapeutics, Doylestown, PA
http://www.hepcomm.com/http://www.hepcomm.com/http://www.hepcomm.com/http://www.hepcomm.com/

5/21/2018 Gish CV July 23 2014

43/225


COMMITTEES:Continued2014Present Member, Editorial Board

BMJ Open Gastroenterology(in association with British Society of Gastroenterology)

5/21/2018 Gish CV July 23 2014

44/225


BOARD ACTIVITIES

19992002 Member, Medical Advisory BoardSchering-PloughInforMed Hepatology

19992002 Cheng Si Yaun, Hong Kong and Beijing, Research and Educationin Liver Disease, Board Member, Peoples Republic of China

20012003 Member, Data Safety Monitoring BoardDepartment of Health and Human Services, National Institutes ofHealth Civacir HCV immunoglobulin protocol

20022010 Chair, U.S. Hepatitis B Advisory BoardBristol-Meyers Squibb Corporation

20022006 At-large Member, Region 5

Organ Allocation Listing CommitteeRegional Review BoardUnited Network for Organ Sharing (UNOS)

20032004 Member, Data Safety Monitoring BoardCivicir Research protocol to prevent recurrent HCV after livertransplantation

1999Present Board Member, Hepatitis C Caring Ambassadors

2007 Editorial Board, Antiviral TherapyManuscript Central

20032006 Member, Advisory BoardLiver Institute for Education and Research (L.I.F.E.R.) Foundation

2004Present Member, Editorial BoardLiver Transplantation

2005Present Member, Editorial Advisory BoardGastroenterology & Hepatology

2007Present Hepatitis B Foundation Medical and Scientific Advisory

2009Present Member, Board of DirectorsHepaHope

2009 Member, International Advisory BoardEgyptian Society of Liver Cancer (ESLC)

2011 Member, Advisory Board, Pharmasset

5/21/2018 Gish CV July 23 2014

45/225


BOARD ACTIVITIES:Continued

1992 Member, Academic Review BoardUniversity of FloridaGainesville, Florida

19921994 Member, Advisory BoardHepatitis B Demonstration Pr

gish cv july 23 2014

Documents

staff positions

business positions

b education

expanded research

research support

teaching activities

board activities

editorial activities